NES Healthcare UK

neshealthcare.co.uk

NES Healthcare has been established for over 25 years. We are the UK’s largest provider of Medical Officers to the Independent Healthcare Sector (private hospitals). We employ over 200 doctors from all over the world, and we currently work with over 100 hospitals and clinics to provide the highest level of patient care. In addition to the Resident Medical Officer (RMO) position, we offer a number of Specialist positions which offer good salaries and opportunities for a better work/life balance.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

CO-DIAGNOSTICS, INC. TO ANNOUNCE EXPANSION OF OEM AGREEMENT WITH BIO MOLECULAR SYSTEMS AT AACC

Co-Diagnostics | July 27, 2022

news image

Co-Diagnostics, Inc. a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be disclosing the global expansion of its OEM agreement with Bio Molecular Systems (BMS) at the Company's customer and distributor update today at AACC. Located in the Gold Coast area of Queensland, Australia, BMS includes the founders and senior personnel from the company responsible for inventing and developing ...

Read More

MEDTECH

NOVOZYMES AND SAIPEM ENTER COLLABORATION AGREEMENT TO CREATE A MORE SUSTAINABLE CO2 CAPTURE

Novozymes | December 13, 2021

news image

Novozymes, the world leader in biological solutions, and Saipem, an advanced technological and engineering platform for safe and sustainable complex infrastructure and plants, have signed a collaboration agreement for the development of innovative solutions for enzymatic carbon capture. As part of the agreement, Saipem - which owns an enzyme-based CO2 capture technology - will be responsible for providing process, mechanical and equipment design, while Novozymes will provide enzym...

Read More

MEDICAL

BIOAGILYTIX TO PURCHASE AUSTRALIA-BASED 360BIOLABS®

BioAgilytix | August 17, 2021

news image

BioAgilytix Labs,a leading global contract research laboratory focused on supporting its pharmaceutical and biotech partners in all stages of large molecule drug development, announced today that it signed a definitive agreement to purchase 360biolabs®, the most comprehensive contract research organization in Australia. The transaction will expand BioAgilytix's global footprint into a jurisdiction of choice to commence first-in-human trials (FIH) and early-phase clinical trials and adds ...

Read More

CELL AND GENE THERAPY

DELFI DIAGNOSTICS SELECTED AS THE LIQUID BIOPSY PARTNER FOR 4-IN-THE-LUNG-RUN: A LARGE-SCALE EUROPEAN LUNG CANCER SCREENING STUDY

Delfi Diagnostics | September 12, 2022

news image

Delfi Diagnostics, a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has been selected as the liquid lung cancer biopsy partner in Europe's multi-national, randomized, prospective lung cancer screening trial known as 4-IN-THE-LUNG-RUN, or 4ITLR. Through 4ITLR, European investigators are studying how often – every year, or every other year – individuals should get screened if their in...

Read More
news image

INDUSTRIAL IMPACT

CO-DIAGNOSTICS, INC. TO ANNOUNCE EXPANSION OF OEM AGREEMENT WITH BIO MOLECULAR SYSTEMS AT AACC

Co-Diagnostics | July 27, 2022

Co-Diagnostics, Inc. a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be disclosing the global expansion of its OEM agreement with Bio Molecular Systems (BMS) at the Company's customer and distributor update today at AACC. Located in the Gold Coast area of Queensland, Australia, BMS includes the founders and senior personnel from the company responsible for inventing and developing ...

Read More
news image

MEDTECH

NOVOZYMES AND SAIPEM ENTER COLLABORATION AGREEMENT TO CREATE A MORE SUSTAINABLE CO2 CAPTURE

Novozymes | December 13, 2021

Novozymes, the world leader in biological solutions, and Saipem, an advanced technological and engineering platform for safe and sustainable complex infrastructure and plants, have signed a collaboration agreement for the development of innovative solutions for enzymatic carbon capture. As part of the agreement, Saipem - which owns an enzyme-based CO2 capture technology - will be responsible for providing process, mechanical and equipment design, while Novozymes will provide enzym...

Read More
news image

MEDICAL

BIOAGILYTIX TO PURCHASE AUSTRALIA-BASED 360BIOLABS®

BioAgilytix | August 17, 2021

BioAgilytix Labs,a leading global contract research laboratory focused on supporting its pharmaceutical and biotech partners in all stages of large molecule drug development, announced today that it signed a definitive agreement to purchase 360biolabs®, the most comprehensive contract research organization in Australia. The transaction will expand BioAgilytix's global footprint into a jurisdiction of choice to commence first-in-human trials (FIH) and early-phase clinical trials and adds ...

Read More
news image

CELL AND GENE THERAPY

DELFI DIAGNOSTICS SELECTED AS THE LIQUID BIOPSY PARTNER FOR 4-IN-THE-LUNG-RUN: A LARGE-SCALE EUROPEAN LUNG CANCER SCREENING STUDY

Delfi Diagnostics | September 12, 2022

Delfi Diagnostics, a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has been selected as the liquid lung cancer biopsy partner in Europe's multi-national, randomized, prospective lung cancer screening trial known as 4-IN-THE-LUNG-RUN, or 4ITLR. Through 4ITLR, European investigators are studying how often – every year, or every other year – individuals should get screened if their in...

Read More